Hazer Group

The Business

Hazer licenses a process that splits natural gas into hydrogen and solid graphite using an iron ore catalyst, avoiding the CO2 by-product of conventional hydrogen production. The company earns no meaningful revenue today; FY26 income of $3.3 million was almost entirely government grants and R&D rebates. Its commercialisation strategy now runs through an alliance with KBR, a top-ten global engineering contractor, which has completed preliminary design work and is meant to carry projects from concept to construction. A pipeline of six named projects spans five countries, but every one remains a non-binding memorandum or feasibility study.

Recent Performance

Hazer fully impaired its Commercial Demonstration Plant during the period, an implicit admission that its build-it-yourself strategy did not work, prompting the pivot to licensing. Commercial revenue stayed near zero. Despite this, the shares have continued to trade on pipeline announcements and partnership news rather than earnings or contracted revenue, holding well above levels the balance sheet or cash position would otherwise justify on their own.

Outlook

We expect revenue to step up materially over the next two years as a first licence fee is assumed to land, before easing back the following year as that upfront payment rolls off, then resuming growth as royalties and a second project layer in. Gross margins should stay high throughout, consistent with an asset-light licensing model where most delivery work sits with KBR. Even so, on our forecasts the business continues to post EBITDA losses through the visible forecast window, narrowing but not closing, meaning Hazer does not reach breakeven within the period we can forecast with reasonable confidence.

Key Risks

Commercialisation failure is the dominant risk: after ten years, Hazer still has zero binding contracts, and a scenario in which no project ever converts implies a very large loss of equity value. Cash runway of roughly 24 months against current burn makes some form of equity raise highly likely within the next couple of years, and if that raise happens from a position of weakness, without a signed contract to support the share price, dilution could be substantial. A third, slower-moving risk sits in the broader hydrogen cost curve: declining electrolyser costs could reach parity with methane pyrolysis economics within a few years, which would permanently narrow Hazer's competitive window regardless of what happens with any individual project.

What to Watch

• 12-24 months FortisBC final investment decision — the thesis-defining event; a positive decision would confirm the first binding commercial licence and materially change the commercial trajectory.
• Q3 FY27 Equity raise announcement — near-certain given the cash runway, and dilutive regardless of pipeline progress.

Latest Developments

The full impairment of the Commercial Demonstration Plant marks the most material recent event, formalising the shift away from owning plants toward pure licensing. It removes a depreciating asset from the balance sheet but does not change the underlying fact that no licence has yet been signed.

Company Description

Hazer Group is an ASX-listed developer of a proprietary methane pyrolysis process that converts natural gas or biomethane into hydrogen and solid graphite, rather than the CO2 produced by conventional steam methane reforming. The business has no operating divisions in the traditional sense; it is effectively one technology asset monetised two ways, direct project licensing and engineering services delivered through its alliance with KBR, which completed the Preliminary Design Package for early projects. Today's income is almost entirely government R&D rebates and grants. The commercial pipeline spans six named projects across Canada, Australia, South Korea, Japan and elsewhere, all still at non-binding memorandum or study stage.

Where the Growth Is

Technology licensing through the KBR alliance is the only growth driver that matters, and it currently contributes nothing: zero binding contracts after more than a decade of development. Our modelling suggests a single licence alone would be value-destructive, generating too little revenue to cover the company's fixed cost base. Multiple conversions, not one, are required for the economics to work, which raises the bar for what "commercial success" actually needs to look like from here.

Competitive Position

Hazer's most defensible advantage is its graphite co-product: it is the only clean hydrogen pathway that produces a saleable carbon by-product, offering a structural economic offset of roughly $500-1,000 per tonne of hydrogen versus pure electrolysis. Around 100 patents protect the underlying catalytic process. That advantage is narrowing, however; we estimate a window of only 2-4 years before declining electrolyser costs reach parity with methane pyrolysis economics. Alternative pyrolysis approaches using plasma or molten metal may also sidestep Hazer's specific catalytic patents. With no operating plant and no binding contract, the technology remains unproven at commercial scale, and the KBR alliance, while credible, is non-exclusive and can be withdrawn if the pipeline stalls.

Management & Capital Discipline

Management has raised roughly $100 million in equity over the company's life against $94 million of accumulated losses, and fully impaired the flagship Commercial Demonstration Plant. A consistent pattern in company communications frames non-binding memoranda and pipeline activity as commercial momentum, while separate risk disclosures admit the technology remains unproven at commercial scale. On the more credible side, a 30% reduction in operating expenses in FY26 shows some capital discipline, but cost-cutting alone does not solve the absence of revenue.

Financial Position

The balance sheet carries no debt, which removes solvency risk from leverage, but cash of roughly $10.7 million against annual burn near $5.2 million gives approximately 24 months of runway. An equity raise is near-certain by mid-FY28 regardless of commercial progress. The company can absorb a modest delay to its pipeline, but it cannot survive an extended downturn in capital markets access without further, likely dilutive, fundraising.